|
UBE2G2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.626032641866E-12 |
| Normal-vs-Stage2 |
1.03190000000364E-06 |
| Normal-vs-Stage3 |
1.62458935193399E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.115400E-01 |
| Stage1-vs-Stage3 |
1.189560E-02 |
| Stage1-vs-Stage4 |
7.993700E-04 |
| Stage2-vs-Stage3 |
8.679200E-03 |
| Stage2-vs-Stage4 |
1.302310E-03 |
| Stage3-vs-Stage4 |
3.572400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.23300000104609E-08 |
| Normal-vs-Asian |
1.7054135881267E-12 |
| Caucasian-vs-AfricanAmerican |
7.851600E-01 |
| Caucasian-vs-Asian |
6.194400E-01 |
| AfricanAmerican-vs-Asian |
5.498600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.55431223447522E-15 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
7.515000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
7.38631378283117E-13 |
| Normal-vs-Age(81-100Yrs) |
2.12209999999047E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.275600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.303400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.395400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.364400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.491600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.123200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.42780000000897E-06 |
| Classical-VS-Follicular |
7.420700E-03 |
| Classical-VS-Other |
3.767800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
8.20729995076874E-09 |
| Tall-VS-Other |
1.658960E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
1.211000E-01 |
| Follicular-VS-Normal |
7.12580000006291E-07 |
| Other-VS-Normal |
4.26099999994989E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.67565961106675E-12 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
2.338700E-03 |
|
|
